Pharmafile Logo

News and Press Releases

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors...

Category: BioManufacturing, Clinical Trials, Other
Posted: July 8, 2024

Myricx
info@myricxbio.com
Myricx Bio Gridiron Building, 1 Pancras Square, King’s Cross, London, N1C 4AG

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Safety of ALX-001 reinforced by new data presented at AD/PD 2024 Conference in Lisbon, Portugal Two oral doses selected for further study in Alzheimer’s and Parkinson’s disease patients. 11 March 2024...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 11, 2024

Allyx Therapeutics
info@allyxthera.com
555 Long Wharf Drive Floor 11 New Haven, CT 06511, US

PlaqueTec closes $8m equity financing

The financing was led by Lord Moynihan of Chelsea alongside The Future Fund, with support from existing investors Funding will support ongoing BIOPATTERN trial and build BIOCARTA database to transform...

Category: Biotechnology, Other, Pharmaceutical
Posted: April 30, 2024

PlaqueTec
info@plaquetec.com
Maia Building (B270) Babraham Research Campus Cambridge CB22 3AT

Experimental gene therapy for giant axonal neuropathy shows promise in NIH clinical trial

Treatment for rare childhood disease was well tolerated and slowed loss of motor function 20 March 2024 -- Maryland, US -- An investigational gene therapy for a rare neurodegenerative disease...

Category: Clinical Trials, Drug Discovery
Posted: March 20, 2024

National Institute of Health (NIH)
olib@od.nih.gov
9000 Rockville Pike Bethesda, Maryland 20892